Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17453383 | 0.87 | UTS2R (0.56) | UTS2RGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17453368 | 0.80 | DYRK1A (0.52) | CLK2GSK3BCDK9CDK5DYRK1A | |
| SCHEMBL16011809 | 0.76 | ALK (0.54) | UTS2RAURKAACVR1ALKGABRA1 | |
| SCHEMBL2628357 | 0.75 | KIF11 (0.46) | UTS2RKIF11AURKADAPK3JAK2 | |
| SCHEMBL30646324 | 0.75 | KIF11 (0.46) | UTS2RKIF11AURKADAPK3JAK2 | |
| SCHEMBL28593610 | 0.75 | ADORA3 (0.53) | AURKAGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2628369 | 0.73 | KIF11 (0.58) | KIF11AURKAGSK3AGSK3BGABRP | |
| SCHEMBL23885174 | 0.72 | RET (0.49) | KIF11AURKAMAP4K4ABL1RET | |
| SCHEMBL30052504 | 0.72 | RET (0.49) | KIF11AURKAMAP4K4ABL1RET | |
| SCHEMBL27209223 | 0.71 | PARG (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2964225-B1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9951061-B2 | CaMKII inhibitors and uses thereof | ALLOSTEROS THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| WO-2016037106-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885KIF11 2930/4885AURKA 411/4885 |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885KIF11 2930/4885AURKA 411/4885 |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885KIF11 2930/4885AURKA 411/4885 |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885KIF11 2930/4885AURKA 411/4885 |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | UTS2R 4564/4885KIF11 2930/4885AURKA 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.